Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer

References

• Pollack A, Hanlon A, Horwitz E, Feigenberg S, Konski A, Movsas B, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionated dose escalation trial. Int J Rad Oncol Biol Phys 2006;64:518–52.
   PubMed Web of Science ®Google Scholar
• Pahlajani N, Ruth K, Buyyounouski M, Chen D, Horwitz E, Hanks G, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate. Int J Rad Oncol Biol Phys 2012;82:1949–56.
   PubMed Web of Science ®Google Scholar
• Leborgne F, Fowler J, Leborgne J, Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Rad Oncol Biol Phys 2012;82:1200–7.
   PubMed Web of Science ®Google Scholar
• Shaffer R, Pickles T, Lee R, Moiseenko V. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure. Int J Rad Oncol Biol Phys 2011;79:1029–36.
   PubMed Web of Science ®Google Scholar
• Lawton C, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Rad Oncol Biol Phys 2007;69:646–55.
   PubMed Web of Science ®Google Scholar
• Adkison J, McHaffie D, Bentzen S, Patel R, Khuntia D, Petereit D, et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Rad Oncol Biol Phys 2012;82:184–90.
   PubMed Web of Science ®Google Scholar
• Quon H, Cheung P, Loblaw D, Morton G, Pang G, Szumacher E, et al. Hypofractionated concominant intensity-modulated radiotherapy boost for high-risk prostate cancer: Late toxicity. Int J Rad Oncol Biol Phys 2012; 82:898–905.
   PubMed Web of Science ®Google Scholar
• Pollack A, Walker G, Buyyounouski M, Horwitz E, Price R, Feigenberg S, et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Rad Oncol Biol Phys 2011;81:S1.
   PubMedGoogle Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v4.0. US Department of Health and Human Services; 2009.
   Google Scholar
• Roach M, Hanks G, Thames H, Schellhammer P, Shipley W, Sokol G, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Rad Oncol Biol Phys 2006;64:965–74.
   Web of Science ®Google Scholar
• Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell S, Lawton C, et al. Whole-pelvis, “mini-pelvis”, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Rad Oncol Biol Phys 2006;66:647–53.
   PubMed Web of Science ®Google Scholar
• Pommier P, Chabaud S, Lagrange J, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25:5366–73.
   PubMed Web of Science ®Google Scholar
• Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, Dielwart M, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–6.
   PubMed Web of Science ®Google Scholar
• Jacob R, Hanlon A, Horwitz, E, Movsas B, Uzzo R, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004;100:538–43.
   PubMed Web of Science ®Google Scholar
• Aizer A, Yu J, McKeon A, Decker R, Colberg J, Peschel R. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Rad Oncol Biol Phys 2009;75: 1344–9.
   PubMed Web of Science ®Google Scholar
• Mantini G, Tagliaferri L, Mattiucci G, Balducci M, Frascino V, Dinapoli N, et al. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation. Int J Rad Oncol Biol Phys 2011;81:e721–6.
   PubMed Web of Science ®Google Scholar
• Kupelian P, Reddy C, Carlson T, Altsman K, Willoughby T. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Rad Oncol Biol Phys 2002;53:904–12.
   PubMed Web of Science ®Google Scholar
• McCammon R, Rusthoven K, Kavanagh B, Newell S, Newman F, Raben D. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Rad Oncol Biol Phys 2009;75: 413–20.
   PubMed Web of Science ®Google Scholar
• Reddy K, Nelson B, McCammon, Newell S, Newman F, Raben D. Preliminary outcomes for the treatment of intermediate- and high-risk prostate cancer patients using pelvic intensity modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate. Int J Rad Oncol Biol Phys 2010;78:S376.
   Google Scholar
• Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari M, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three- dimensional conformal radiotherapy for prostate cancer. Int J Rad Oncol Biol Phys 2011;79:1013–21.
   PubMed Web of Science ®Google Scholar
• Kupelian P, Willoughby T, Reddy C, Klein E, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Rad Oncol Biol Phys 2007;68:1424–30.
   PubMed Web of Science ®Google Scholar